A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

NCT04645966 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

326

Enrollment

INDUSTRY

Sponsor class

Stopped The Sponsor decided to discontinue the study based on Sponsor's careful review of available safety data in concert with the recommendation of an independent Data Monitoring Committee.

Conditions

Meningococcal Vaccine

Interventions

BIOLOGICAL: MenABCWY
BIOLOGICAL: Bivalent rLP2086 (60-µg Dose)
BIOLOGICAL: Bivalent rLP2086 (120-µg Dose)
BIOLOGICAL: Bexsero
DRUG: Prophylactic Liquid Paracetamol (PLP)
BIOLOGICAL: Nimenrix
OTHER: Placebo
DRUG: Scheduled Liquid Paracetamol (SLP)
DRUG: Therapeutic Liquid Paracetamol (TLP)

Sponsor

Pfizer